Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Infliximab in the Treatment of Chinese Subjects With Moderate to Severe Plaque-type Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2014
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Xian-Janssen
- 21 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Oct 2010 Actual end date (February 2010) added as reported by ClinicalTrials.gov.
- 21 Aug 2010 New trial record